Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $4.09, but opened at $3.87. Inventiva shares last traded at $4.09, with a volume of 461,113 shares changing hands.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IVA shares. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial started coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and a consensus target price of $16.56.

Inventiva Stock Up 4.7%

The company’s fifty day simple moving average is $5.29 and its two-hundred day simple moving average is $5.41.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million for the quarter. On average, equities research analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Creative Planning bought a new position in shares of Inventiva during the second quarter worth approximately $32,000. Virtu Financial LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $84,000. Cerity Partners LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $93,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter valued at approximately $116,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.